KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Other Operating Expenses: 2010-2025

Historic Other Operating Expenses for TherapeuticsMD (TXMD) over the last 12 years, with Sep 2025 value amounting to $128,000.

  • TherapeuticsMD's Other Operating Expenses rose 33.33% to $128,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $514,000, marking a year-over-year decrease of 79.37%. This contributed to the annual value of $1.8 million for FY2024, which is 116.18% up from last year.
  • TherapeuticsMD's Other Operating Expenses amounted to $128,000 in Q3 2025, which was up 33.33% from $96,000 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Other Operating Expenses registered a high of $32.2 million during Q2 2021, and its lowest value of -$93.3 million during Q4 2021.
  • Over the past 3 years, TherapeuticsMD's median Other Operating Expenses value was $130,500 (recorded in 2024), while the average stood at $375,750.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first tumbled by 458.82% in 2021, then surged by 110.79% in 2022.
  • Over the past 5 years, TherapeuticsMD's Other Operating Expenses (Quarterly) stood at -$93.3 million in 2021, then surged by 110.79% to $10.1 million in 2022, then crashed by 91.83% to $822,000 in 2023, then tumbled by 86.98% to $107,000 in 2024, then skyrocketed by 33.33% to $128,000 in 2025.
  • Its Other Operating Expenses stands at $128,000 for Q3 2025, versus $96,000 for Q2 2025 and $183,000 for Q1 2025.